Two weeks ago (19 Mar), a federal jury in San Francisco found Monsanto’s Roundup weed killer was a substantial factor in causing cancer in a Californian man, Edwin Hardeman. Mr Hardeman was the first person to challenge Monsanto’s Roundup in a federal court. During the trial, the 70-year-old testified that he had use the weed killer for a long period of time and at one time got it on his skin before he was diagnosed with cancer.

The ruling at the federal court followed a historic verdict last August in which a California state court ruled that Roundup caused the terminal cancer of Dewayne Johnson, a former school groundskeeper. In Mr Johnson’s case, the jury found Monsanto had “acted with malice or oppression” and awarded him US$289 million in damages. The damages were later reduced to US$78 million.

After the federal court found Monsanto’s weed killer was responsible for Mr Hardeman’s cancer, the jury deliberated on the damages to be awarded to Mr Hardeman last Wed (27 Mar) and decided on the amount of US$80 million. The jury found the German pharmaceutical giant Bayer liable because its subsidiary, Monsanto, did not warn the plaintiff of the herbicide’s alleged cancer risks.

Not surprisingly, Bayer share price dropped. It has been steadily sinking since the first adverse verdict in the Roundup lawsuit was announced last August. The drop in share price has pushed Bayer’s value down to about US$58 billion since then. It is now trading at below 60 EUR.

In fact, it was Singapore’s Temasek Holdings which helped Bayer to acquire Monsanto. It was reported in Apr last year that Bayer sold 3.6 per cent stake to Temasek for 3 billion euros at 96.77 euros per share. The money is used as part of Bayer’s plan to takeover Monsanto. Together with its existing holding in Bayer, Temasek would then own about 4 percent in Bayer after the transaction. By Jun, with Temasek’s help, Bayer successfully acquired Monsanto to become the biggest seed and agricultural chemical maker in the world.

As of Friday’s (29 Mar) closing, Bayer’s share price was 57.60 euros. Since Temasek bought 3 billion euros worth of shares at 96.77 euros in Apr last year, that means it has lost 39.17 euros per share or 40.5% of the 3 billion euros investment. So, in less than a year, Temasek has lost at least 1.2 billion euros or S$1.85 billion.

Bayer continues to deny that Roundup could cause cancer, “This (second) verdict does not change the weight of over four decades of extensive science and the conclusions of regulators worldwide that support the safety of our glyphosate-based herbicides and that they are not carcinogenic.”

Third trial against Monsanto started

The Hardeman trial is only the second of more than 11,200 Roundup lawsuits set to go to trial in the US.

A third Roundup lawsuit started in California’s Superior Court in Oakland last Thu (28 Mar). It was brought by California elderly couple Alva and Alberta Pilliod who were diagnosed with non-Hodgkin’s lymphoma in 2011 and 2015 respectively.

Alva was diagnosed with systemic non-Hodgkin lymphoma in 2011 and has been in remission since, after undergoing aggressive chemotherapy treatment that degraded his cognitive function. Alberta was diagnosed with the same cancer in 2015 after doctors found a tumor in the middle of her brain. She was declared cancer-free in 2016 following a round of chemotherapy that left her with extensive brain damage, but relapsed the next year. A second round of treatment stabilized the tumor.

The probability that both Alva and Alberta would get non-Hodgkin lymphoma is 1 in 20,000, the plaintiffs’ lawyer told the jury. Their treating physician said it was so unlikely they would both develop the same cancer that an environmental factor like Roundup was the likely culprit.

The plaintiffs’ lawyer also revealed new evidence in court, alleging that Monsanto planted one of its employees at a contract lab called Industrial Bio-Test Laboratories (IBT) in the 1970s to fake negative mouse carcinogenicity data for Roundup’s active ingredient glyphosate. The alleged fake data would then be used to win regulatory approval for the weed killer in 1975. The lawyer also alleged that Monsanto had planned an attack to discredit the World Health Organization’s (WHO) cancer research agency, anticipating that it would classify glyphosate as a probable human carcinogen in 2015.

Furthermore, the lawyer intended to show that Monsanto had exploited “deep connections” within the US Environmental Protection Agency (EPA) to classify glyphosate as non-carcinogenic. In fact, a toxicologist in the University of California at Berkeley, was “so outraged” by the EPA’s failure to follow its own herbicide-assessment guidelines that she recently resigned from an EPA glyphosate-review panel to conduct her own study of the chemical. That study, released this past February, found that glyphosate exposure increases the risk of developing non-Hodgkin lymphoma.

The lawyer told the jury in the third trial that Monsanto has known for 40 years that Roundup causes tumors in rodents and for 20 years that it causes non-Hodgkin lymphoma in humans, but refused to include a cancer warning to safeguard the enormous profits generated by the most widely used herbicide in the world.

“You give the consumer the right to make a choice” about a chemical that “causes cancer before they buy it,” he said. “Because that failure means people get hurt, and they have to deal with the consequences. That’s how it works.”

The latest new evidence against Monsanto in the third trial was not presented in the previous two trials, where both juries found Monsanto liable nonetheless.

Meanwhile, Monsanto’s lawyer argued that the elderly couple already have several known risk factors for non-Hodgkin lymphoma. Alva has a history of skin cancer – he has been diagnosed with multiple forms of it 22 times – the autoimmune disorder ulcerative colitis, and five bouts of meningitis. The lawyer said that auto-immune conditions like ulcerative colitis increase the risk of developing non-Hodgkin lymphoma. And meningitis is “an extremely rare condition” that weakened Alva’s immune system, he said.

Monsanto’s lawyer also pointed out that Alberta had bladder cancer before, which more than doubles the risk of non-Hodgkin lymphoma and Hashimoto’s disease, a condition in which the immune system attacks the thyroid gland. With this condition, the risk of non-Hodgkin lymphoma is tripled, he said.

He rounded out his remarks by noting that 100 countries have deemed Roundup safe to sell since the herbicide was developed in 1974. He added that regulators in the US, Canada and Europe re-reviewed glyphosate after the WHO’s cancer agency announced its findings and again concluded that glyphosate is safe.

“When you see the EPA’s determination,” the Monsanto’s lawyer said, “it is backed by solid science.”

Other than California, Monsanto’s Roundup weed killer trials are also expected to start in other States soon. For example, at least two trials are scheduled to take place in St. Louis, Missouri state court in the second half of this year.

Even as more cases are waiting to be heard in US courts, more cancer sufferers are also queuing up to file suits against Monsanto. Do expect Bayer’s share price to tank further if Monsanto continues to lose more Roundup lawsuits.

 

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

Singaporeans also subjected to hate speech

By Lina Chiam – Senior Parliamentary Secretary Ms Sim Ann has spoken…

MNC’s foreign hiring manager relocates from HK to SG and proceeds to replace SG PMET with HK lady

Recently, a Singaporean PMET working for Refinitiv Asia (the Financial & Risk…

【冠状病毒19】无需再依据身份证尾号 环境局放宽湿巴刹人流管制

自本周末(9月12日)开始,将放宽的四家本地巴刹人数管制,人们无需再依据身份证号码的尾数进入巴刹。 有关的四家湿巴刹为芽笼士乃巴刹、义顺环路第104/105栋的忠邦城湿巴刹、马西岭巷第20/21栋组屋的湿巴刹,以及位于裕廊西52街第505栋的湿巴刹。 虽然无需再根据身份证号码尾数进入湿巴刹,但是民众还是必须使用SafeEntry访客登记系统,以及遵守一米的安全社交距离。 根据身份证尾数限定进入湿巴刹的措施,是于今年4月22日开始实施。而环境局指出,当限制措施于8月13日开始,在工作日开始放缓后,湿巴刹外的人群管理和排队情况一直维持在可控制范围内。 尤其是在马西岭和芽笼士乃的湿巴刹外,工作日几乎看不到有排队的情况出现。 据当局调查,四个湿巴刹在工作日的平均客流量有显着增加,增幅约18巴仙至48巴仙之间。“这为湿巴刹摊贩带来更多生意,同时也为到来的客户提供更大的灵活性。” 当局也察觉到,周末的人流和过去三周相比并没有很大变化,且很少客户从周末转改到工作日进行购物。 芽笼士乃湿巴刹的人流量最多,甚至有逾百人在湿巴刹外排队的情况出现,;而马西岭的人流也不少,排队人数可多达70人,。另外两个湿巴刹则没有出现排队的现象。 在高峰时段,排队进入芽笼士乃湿巴刹的客户需耗时约20分钟,在马西岭湿巴刹排队则需花费15分钟。然而,环境局认为这都是在可“控制的排队时间”内。

【舆论】李显扬:新加坡人的胜利

在昨天(7月10日)举行的大选中,新加坡公民充分地展现了忠于国家,热爱国家,自豪地说出:“我们是新加坡公民”,并投票给反对党。 对于PAP而言,这次在危机选举应该是轻而易举的。PAP早前预测,如同911恐怖袭击事件和李光耀逝世一般,新冠肺炎疫情也会“拯救”该党。此次大选,新加坡公民拒绝让PAP利用危机来牟取政党利益。PAP的得票率重挫,反对党成功赢得自独立以来的最多席位。 反对党在东部和西部都有所斩获。 新加坡公民表达了对阿裕尼—后港市镇理事会(AHTC)和龌龊政治等攻击的排斥。PAP第四代领导层的选举成绩,清楚地显示选民并不为所动。 工人党(Workers Party) 的竞选成绩单靓丽,赢得2席集选区(GRC)和1席单选区(SMC)。这展现了该党出色的领导层,党领导层更迭的能力,并选派强大、有朝气、年轻和多元的团队上阵。从之前被视为华人政党,如今该党体现朝向真正多元种族新加坡的方向。这确实值得嘉许。新加坡民主党(SDP)也获得非常亮丽的成绩,赢获45/46% 的得票率。 在新冠肺炎大选中,与PAP制度化的巨兽展开对抗的崭新政党 — 新加坡前进党(PSP),也受到选民的欢迎,获得逾40%的得票率。即便仅是这一点,便是非常杰出的成就。 西部,传统上是PAP的堡垒区。前进党差些就拿下西海岸集选区。我的朋友陈清木医生和其PSP团队,成功开拓美好的开始,非常棒。我知道,你们将以此为第一步,致力于创造拥有良好价值及与人民为本的新加坡。…